Argenx vs Biomarin Pharmaceutical
Argenx is the larger business, with $4.15bn of revenue in fiscal 2025 against $3.22bn for Biomarin Pharmaceutical (1.3 times as much). Argenx grew faster (89.9% against 12.9%). Argenx kept more of each dollar of sales as profit: a net margin of 31.1% against 10.8%. Argenx carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | ArgenxARGX, 2025 | Biomarin PharmaceuticalBMRN, 2025 |
|---|---|---|
| Revenue | $4.15bn | $3.22bn |
| Revenue growth | 89.9% | 12.9% |
| Net income | $1.29bn | $349m |
| Operating margin | 25.4% | 12.7% |
| Net margin | 31.1% | 10.8% |
| Return on equity | 20.2% | 5.9% |
| Free cash flow | $679m | $725m |
| Cash | $3.49bn | $1.31bn |
| Total debt | $0 | $600m |
| Debt to equity | 0.0% | 9.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 3,221 |
| Market value | $55.65bn | $10.80bn |
| Price vs our value range | — | Within our value range |
| Moat score | — | 40 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 5 sales |